乳腺癌原发灶及腋窝淋巴结18F-FDG PET或PET/CT所测SUVmax的预后价值
该系统评价与Meta分析纳入15项研究共3574例乳腺癌患者,评估治疗前原发灶及腋窝淋巴结SUVmax的预后价值。原发灶高SUVmax与无事件生存期较差相关(合并HR 1.96,95%CI 1.40-2.73),在浸润性导管癌患者中合并HR为1.91(95%CI 1.40-2.64);腋窝淋巴结SUVmax及N/T比值、总生存期的合并HR置信区间均跨1,未达统计学显著。
要点
- 原发灶高SUVmax与无事件生存期较差相关,合并HR 1.96(95%CI 1.40-2.73)。
- 浸润性导管癌患者中原发灶SUVmax合并HR 1.91(95%CI 1.40-2.64)。
- 腋窝淋巴结SUVmax及N/T比值、总生存期的合并HR置信区间均跨1,未达统计学显著。
核心结论
- 原发灶高SUVmax的患者可能面临更高的复发风险或较差的进展,18F-FDG SUVmax在浸润性导管癌患者中显示出显著的预后价值。
研究设计与样本
- 系统评价与Meta分析,系统检索PubMed、Embase和Cochrane Library,纳入15项研究共3574例乳腺癌患者,主要终点为无事件生存期,次要终点为总生存期,采用随机效应模型估算合并HR。
诊断标准与关键数值
- 原发灶高SUVmax对无事件生存期的合并HR为1.96(95%CI 1.40-2.73)。
- 腋窝淋巴结高SUVmax对无事件生存期的合并HR为1.89(95%CI 0.70-5.07),未达统计学显著。
- 腋窝淋巴结与原发灶SUVmax比值(N/T比值)对无事件生存期的合并HR为2.06(95%CI 0.59-7.21),未达统计学显著。
- 浸润性导管癌患者原发灶SUVmax对无事件生存期的合并HR为1.91(95%CI 1.40-2.64)。
- 原发灶SUVmax对总生存期的合并HR为0.64(95%CI 0.23-1.84),腋窝淋巴结SUVmax对总生存期的合并HR为1.09(95%CI 0.07-16.53),均未达统计学显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the prognostic value of maximum standardized uptake values (SUVmax) measured in the primary lesion and axillary lymph nodes (ALN) by pretreatment fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) in patients with breast cancer.
METHODS: We systematically searched PubMed, Embase, and the Cochrane Library. The primary prognosis endpoint was event-free survival (EFS), and the secondary endpoint was overall survival (OS). The pooled hazard ratio (HR) was estimated by using random-effects model according to the results of heterogeneity.
RESULTS: Fifteen eligible studies with 3574 breast cancer patients were included. For EFS, patients with higher primary SUVmax showed a poorer survival prognosis with pooled HR of 1.96 (95% confidence interval (CI) 1.40-2.73). The combined HR of high SUVmax in ALN and ALN-to-primary SUVmax ratio (N/T ratio) were 1.89 (95% CI 0.70-5.07) and 2.06 (95% CI 0.59-7.21), respectively. In analyzing invasive ductal carcinoma (IDC) patients, the pooled HR was 1.91 (95% CI 1.40-2.64). For OS, the pooled HR of SUVmax in primary lesion and ALN were 0.64 (95% CI 0.23-1.84) and 1.09 (95% CI 0.07-16.53), respectively.
CONCLUSIONS: Our meta-analysis suggested that patients with high primary SUVmax may experience a higher risk for recurrence or a poor progression. Moreover, the SUVmax of 18F-FDG showed a significant prognostic value in IDC patients.
引用
- Diao W, Tian F, Jia Z, et al. The prognostic value of SUVmax measuring on primary lesion and ALN by 18F-FDG PET or PET/CT in patients with breast cancer. Eur J Radiol. 2018. PMID: 30017264. doi:10.1016/j.ejrad.2018.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。